Iron Deficiency Anemia Market Report 2026

The iron deficiency anemia market size has grown strongly in recent years. It will grow from $3.57 billion in 2025 to $3.79 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to high prevalence of nutritional iron deficiency, widespread use of oral iron supplements, chronic blood loss from gastrointestinal disorders, maternal anemia in developing regions, limited access to advanced parenteral therapies.

The iron deficiency anemia market size is expected to see strong growth in the next few years. It will grow to $4.78 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising global anemia burden, increasing adoption of intravenous iron therapies, growth in geriatric population, expanding healthcare access in emerging markets, improved diagnostic and screening initiatives. Major trends in the forecast period include rising adoption of parenteral iron therapies, increasing focus on maternal and pediatric anemia management, growing use of high-dose and long-acting iron formulations, expansion of home-based iron therapy and infusion services, increasing awareness and screening programs for iron deficiency.

The rising incidence of nutritional deficiencies is expected to drive the growth of the iron deficiency anemia market in the coming years. Nutritional deficiency is a condition that arises when the body does not receive adequate amounts of one or more essential nutrients, such as vitamins, minerals, proteins, or fats, necessary for maintaining optimal health. The prevalence of nutritional deficiencies is increasing due to poor dietary habits, including the widespread intake of processed foods and food insecurity, which restricts access to nutrient-rich options in lower-income populations. Iron deficiency anemia is a prevalent type of nutritional deficiency in which insufficient iron intake reduces the number of red blood cells, limiting the body’s capacity to transport oxygen. For example, in February 2025, the World Health Organization, a Switzerland-based intergovernmental organization, estimated that anemia affects 40% of children aged 6-59 months, 37% of pregnant women, and 30% of women aged 15-49 years. Consequently, the growing prevalence of nutritional deficiencies fuels the demand in the iron deficiency anemia market.

Major companies in the iron deficiency anemia market are concentrating on developing innovative solutions, such as intravenous iron injections, to provide an optimal combination of nutrients that improve absorption and enhance tolerance, effectively combating iron deficiency. Intravenous iron injection is a medical procedure used to deliver iron directly into the bloodstream to treat iron deficiency or anemia when oral supplements are ineffective or inadequate. For example, in March 2024, Cadila Pharmaceuticals, an India-based pharmaceutical company, introduced Redshot FCM, an intravenous iron injection formulated with ferric carboxymaltose to efficiently treat iron deficiency anemia (IDA). This innovative product is suitable for both adults and children over one year old who cannot tolerate oral iron supplements. With a strong safety profile and minimal risk of anaphylaxis, Redshot FCM allows high doses of iron to be administered in a single session, enabling rapid improvement in hemoglobin levels. It is particularly beneficial for vulnerable populations such as pregnant women, the elderly, and cancer patients.

In May 2025, SteinCares, a Costa Rica-based specialty healthcare company, collaborated with Pharmacosmos A/S to broaden access to intravenous iron replacement therapy across Latin America. Through this collaboration, SteinCares and Pharmacosmos aim to enhance the availability of Monofer, a treatment for iron deficiency with or without anemia, to improve clinical outcomes, increase patient convenience through efficient therapy delivery, and support wider access across therapeutic areas including nephrology, cardiology, onco-hematology, gastroenterology, gynecology, and obstetrics. Pharmacosmos A/S is a Denmark-based pharmaceutical company focused on developing, manufacturing, and marketing treatments for iron deficiency and iron deficiency anemia.

Major companies operating in the iron deficiency anemia market are Sanofi S.A., Abbott Laboratories, Fresenius SE & Co. KGaA, Sandoz International GmbH, Perrigo Company, Cipla Limited, Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Zydus Cadila, Lupin Limited, Alkem Laboratories Limited, AMAG Pharmaceuticals Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, AdvaCare Pharma LLC.

North America was the largest region in the iron deficiency anemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the iron deficiency anemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the iron deficiency anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the iron deficiency anemia market by increasing costs for imported active pharmaceutical ingredients, injectable iron formulations, and infusion-related supplies. Hospital pharmacies and parenteral iron therapy segments are most affected, particularly in import-dependent regions such as asia pacific and latin america. These tariffs may slow adoption of advanced iron formulations. However, they are also encouraging local manufacturing, generic product development, and supply chain diversification to stabilize long-term availability.

The iron deficiency anemia market research report is one of a series of new reports that provides iron deficiency anemia market statistics, including iron deficiency anemia industry global market size, regional shares, competitors with a iron deficiency anemia market share, detailed iron deficiency anemia market segments, market trends and opportunities, and any further data you may need to thrive in the iron deficiency anemia industry. This iron deficiency anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Iron deficiency anemia is a condition in which the body does not have enough iron to produce a sufficient amount of hemoglobin, a protein in red blood cells responsible for carrying oxygen throughout the body. Iron deficiency may result from inadequate dietary intake, poor iron absorption, blood loss, or increased iron requirements, such as during pregnancy.

The primary treatment options for iron deficiency anemia include oral iron therapy, parenteral iron therapy, and red blood cell transfusion. Oral iron therapy consists of taking iron supplements by mouth, such as tablets, capsules, or liquids, to elevate iron levels in the body. These supplements are supplied through hospital pharmacies, drug stores, retail pharmacies, and online pharmacies, serving various end users, including hospitals, clinics, and home healthcare.

The iron deficiency anemia market includes revenues earned by entities by providing services such as iron supplementation, bone marrow biopsy, complete blood count (CBC), and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.